

DEXTROSE- dextrose monohydrate injection, solution
Hospira, Inc.

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

50% Dextrose Injection, USP
Concentrated Dextrose for
Intravenous Administration

NOTE: This solution is hypertonic — See WARNINGS and PRECAUTIONS.

LifeShield™ Abboject® Syringe Fliptop Container

Ansyr™ Plastic Syringe

Ansyr™II Plastic Syringe

R_x only


DESCRIPTION

50% Dextrose Injection, USP is a sterile, nonpyrogenic, hypertonic solution of dextrose in water for injection for intravenous injection as a fluid and nutrient replenisher.

Each mL of fluid contains 0.5 g dextrose, hydrous which delivers 3.4 kcal/gram. The solution has an osmolarity of 2.53 mOsmol/mL (calc.), a pH of 4.2 (3.2 to 6.5) and may contain sodium hydroxide and/or hydrochloric acid for pH adjustment.

The solution contains no bacteriostat, antimicrobial agent or added buffer (except for pH adjustment) and is intended only for use as a single-dose injection. When smaller doses are required, the unused portion should be discarded with the entire unit.

Dextrose, USP is chemically designated C₆H₁₂O₆ · H₂O (D-glucose monohydrate), a hexose sugar freely soluble in water. Dextrose, hydrous has the following structural formula:



Water for Injection, USP is chemically designated H₂O.

The syringe is molded from a specially formulated polypropylene. Water permeates from inside the container at an extremely slow rate which will have an insignificant effect on solution concentration over the expected shelf life. Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the syringe material.

CLINICAL PHARMACOLOGY

When administered intravenously this solution restores blood glucose levels in hypoglycemia and provides a source of carbohydrate calories.

Carbohydrate in the form of dextrose may aid in minimizing liver glycogen depletion and exerts a protein-sparing action. Dextrose injection undergoes oxidation to carbon dioxide and water.

Water is an essential constituent of all body tissues and accounts for approximately 70% of total body weight. Average normal adult requirement ranges from two to three liters (1.0 to 1.5 liters each for insensible water loss by perspiration and urine production).

Water balance is maintained by various regulatory mechanisms. Water distribution depends primarily on the concentration of electrolytes in the body compartments and sodium (Na^+) plays a major role in maintaining physiologic equilibrium.

INDICATIONS AND USAGE

50% Dextrose Injection is indicated in the treatment of insulin hypoglycemia (hyperinsulinemia or insulin shock) to restore blood glucose levels.

The solution is also indicated, after dilution, for intravenous infusion as a source of carbohydrate calories in patients whose oral intake is restricted or inadequate to maintain nutritional requirements. Slow infusion of hypertonic solutions is essential to insure proper utilization of dextrose and avoid production of hyperglycemia.

CONTRAINDICATIONS

A concentrated dextrose solution should not be used when intracranial or intraspinal hemorrhage is present, nor in the presence of delirium tremens if the patient is already dehydrated.

Dextrose injection without electrolytes should not be administered simultaneously with blood through the same infusion set because of the possibility that pseudoagglutination of red cells may occur.

WARNINGS

50% Dextrose Injection is hypertonic and may cause phlebitis and thrombosis at the site of injection.

Significant hyperglycemia and possible hyperosmolar syndrome may result from too rapid administration. The physician should be aware of the symptoms of hyperosmolar syndrome, such as mental confusion and loss of consciousness, especially in patients with chronic uremia and those with known carbohydrate intolerance.

The intravenous administration of this solution can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema.

Additives may be incompatible. Consult with pharmacist if available. When introducing additives, use aseptic technique, mix thoroughly and do not store.

For peripheral vein administration

The solution should be given slowly, preferably through a small bore needle into a large vein, to minimize venous irritation.

For central venous administration

Concentrated dextrose should be administered via central vein only after suitable dilution.

PRECAUTIONS

Do not use unless the solution is clear and seal is intact. Discard unused portion.

Electrolyte deficits, particularly in serum potassium and phosphate, may occur during prolonged use of concentrated dextrose solutions. Blood electrolyte monitoring is essential and fluid and electrolyte imbalances should be corrected. Essential vitamins and minerals also should be provided as needed.

To minimize hyperglycemia and consequent glycosuria, it is desirable to monitor blood and urine glucose and if necessary, add insulin.

When a concentrated dextrose infusion is abruptly withdrawn, it is advisable to follow with the administration of 5% or 10% dextrose injection to avoid rebound hypoglycemia.

Solutions containing dextrose should be used with caution in patients with known subclinical or overt diabetes mellitus.

Care should be exercised to insure that the needle is well within the lumen of the vein and that extravasation does not occur. If thrombosis should occur during administration, the injection should be stopped and corrective measures instituted.

Concentrated dextrose solutions should not be administered subcutaneously or intramuscularly.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Studies with solutions in polypropylene syringes have not been performed to evaluate carcinogenic potential, mutagenic potential or effects on fertility.

Pregnancy Category C

Animal reproduction studies have not been conducted with dextrose. It is also not known whether dextrose can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Dextrose should be given to a pregnant woman only if clearly needed.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when 50% Dextrose Injection, USP is administered to a nursing mother.

ADVERSE REACTIONS

Hyperosmolar syndrome, resulting from excessively rapid administration of concentrated dextrose may cause mental confusion and/or loss of consciousness.

Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.

If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

OVERDOSAGE

In the event of overhydration or solute overload during therapy, re-evaluate the patient and institute appropriate corrective measures. See **WARNINGS** and **PRECAUTIONS**.

DOSAGE AND ADMINISTRATION

For peripheral vein administration

Injection of the solution should be made *slowly*.

The maximum rate at which dextrose can be infused without producing glycosuria is 0.5 g/kg of body weight/hour. About 95% of the dextrose is retained when infused at a rate of 0.8 g/kg/hr.

In insulin-induced hypoglycemia, intravenous injection of 10 to 25 grams of dextrose (20 to 50 mL of 50% dextrose) is usually adequate. Repeated doses and supportive treatment may be required in severe cases. A specimen for blood glucose determination should be taken before injecting the dextrose. In such emergencies, dextrose should be administered promptly without awaiting pretreatment test results.

For central venous administration

For total parenteral nutrition 50% Dextrose Injection, USP is administered by slow intravenous infusion (a) after admixture with amino acid solutions via an indwelling catheter with the tip positioned in a large central vein, preferably the superior vena cava, or (b) after dilution with sterile water for injection. Dosage should be adjusted to meet individual patient requirements.

Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.

The maximum rate of dextrose administration which does not result in glycosuria is the same as cited above.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. See **CONTRAINDICATIONS**.

HOW SUPPLIED

50% Dextrose Injection, USP is supplied in single-dose containers as follows:

NDC No.	Container	Size
0409-4902-34	LifeShield Abboject® Unit of Use Syringe with male luer lock adapter and protected needle	25 g in 50 mL
0409-6648-02	Fliptop Vial	25 g in 50 mL
0409-7517-15	Ansy TM Plastic Syringe	25 g in 50 mL
0409-7517-16	Ansy TM II Plastic Syringe with syringe and barrel detached	25 g in 50 mL

Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from freezing. Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]

October, 2009

Hospira, Inc., Lake Forest, IL 60045 USA

EN-2278

Abboject® is a trademark of the Abbott group of companies.

PRINCIPAL DISPLAY PANEL - 50 mL Syringe Label - 0409-7517-15

50% DEXTROSE

50 mL Single-dose
NDC 0409-7517-15

50% DEXTROSE Injection, USP

25 grams (0.5 g/mL)

Rx only

For I.V. use. Usual dosage: See insert. Sterile, nonpyrogenic.
2.53 mOsmol/mL (calc.). pH 4.2 (3.2 to 6.5)

Hospira

RL-0628 (10/04)

Hospira, Inc., Lake Forest, IL 60045 USA

50% DEXTROSE

Approx. mL 5 10 15 20 25 30 35 40 45 50

50 mL Single-dose NDC 0409-7517-15

50% DEXTROSE Injection, USP

25 grams (0.5 g/mL) Rx only

For I.V. use. Usual dosage: See insert. Sterile, nonpyrogenic.
2.53 mOsmol/mL (calc.). pH 4.2 (3.2 to 6.5)

Hospira

RL-0628 (10/04)

(01) 0 030409 751715 2

Hospira, Inc., Lake Forest, IL 60045 USA

PRINCIPAL DISPLAY PANEL - 50 mL Syringe Carton - 0409-7517-15

50 mL
NDC 0409-
7517-15

**50 %
DEXTROSE**

Injection, USP

25 grams (0.5 g/mL)

Ansy[®]

Unit of Use Syringe

**LifeShield[®] with male luer
lock adapter**


Rx only

Hospira


▣ **PRESS AND PULL TO OPEN** ▣

USE ASEPTIC TECHNIQUE

1. Remove luer cover.



2. Hold plunger and push barrel forward to relieve any resistance that may be present.



3. Pull the barrel down until air is expelled from the syringe.



50% DEXTROSE
Injection, USP
25 grams (0.5 g/mL)

Each mL contains dextrose, hydrous 0.5 grams. May contain NaOH and/or HCl for pH adjustment. 2.53 mOsmol/mL (calc.). Medication and fluid path are sterile and nonpyrogenic if cap is in place and package is intact.

pH 4.2 (3.2 to 6.5).

Hospira

50% DEXTROSE
Injection, USP
25 grams (0.5 g/mL)

50 mL NDC 0409-7517-15

OP EN

▶ PRESS AND PULL TO OPEN ◀

50 mL NDC 0409-7517-15

50% DEXTROSE
Injection, USP
25 grams (0.5 g/mL)

Ansy[®]

Unit of Use Syringe

LifeShield[®] with male luer lock adapter

R_x only

Single-dose unit. Discard unused portion. For intravenous use. Usual dosage: See insert. Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]

Hospira

50% DEXTROSE
Injection, USP

25 grams (0.5 g/mL)

Hospira



CA-0432 (10/04)
©Hospira 2004 Printed in USA
Hospira, Inc.
Lake Forest, IL 60045 USA



PRINCIPAL DISPLAY PANEL - 50 mL Syringe Label - 0409-7517-16

50% DEXTROSE

50 mL Single-dose
NDC 0409-7517-16


50% DEXTROSE Injection, USP
25 grams (0.5 g/mL)

Rx only

For I.V. use. Usual dosage: See insert. Sterile, nonpyrogenic.
2.53 mOsmol/mL (calc.). pH 4.2 (3.2 to 6.5)

Hospira

RL-0629 (10/04)



PRINCIPAL DISPLAY PANEL - 50 mL Syringe Carton - 0409-7517-16

50 mL

NDC 0409-7517-16

50 %

DEXTROSE

Injection, USP

25 grams (0.5 g/mL)

Ansy[®] II

Unit of Use Syringe

LifeShield[®]

with male luer lock adapter


Rx only

Hospira


▣ PRESS AND PULL TO OPEN ▣

USE ASEPTIC TECHNIQUE


1. Assemble plunger to syringe.




2. Remove luer cover.



3. Hold plunger and push barrel forward to relieve any resistance that may be present.



4. Pull the barrel down until air is expelled from the syringe.



©Hospira 2004 CA-0433 (10/04) Printed in USA
Hospira, Inc., Lake Forest, IL 60045 USA

50 mL NDC 0409-7517-16

50% DEXTROSE
Injection, USP

25 grams (0.5 g/mL)

50% DEXTROSE
Injection, USP

25 grams (0.5 g/mL)

50% DEXTROSE
Injection, USP

25 grams (0.5 g/mL)

Ansyr® II

Unit of Use Syringe

LifeShield®
with male luer lock adapter

Rx only

Hospira

50 mL NDC 0409-7517-16

50% DEXTROSE
Injection, USP

25 grams (0.5 g/mL) **Hospira**

Single-dose unit. Discard unused portion. For intravenous use. Usual dosage: See insert. Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Each mL contains dextrose, hydrous 0.5 grams. May contain NaOH and/or HCl for pH adjustment. 2.53 mOsmol/mL (calc.). pH 4.2 (3.2 to 6.5). Medication and fluid path are sterile and nonpyrogenic if cap is in place and package is intact.

OP EN

OP EN

OP EN

OP EN

← PRESS AND PULL TO OPEN →

← PRESS AND PULL TO OPEN →

← PRESS AND PULL TO OPEN →

← PRESS AND PULL TO OPEN →

Barcode: (01) 0 050409 751716 9

PRINCIPAL DISPLAY PANEL - 50 mL Syringe Label - 0409-4902-34

50% DEXTROSE

50 mL Single-dose
NDC 0409-4902-34

50% DEXTROSE Inj., USP
25 grams (0.5 g/mL)

For I.V. use. Usual dosage: See insert.
Sterile, nonpyrogenic.
2.53 mOsmol/mL (calc.)
pH 4.2 (3.2 to 6.5)

Rx only

Hospira

RL-0239 (5/04)

Hospira, Inc., Lake Forest, IL 60045 USA

50% DEXTROSE

Approx. mL
0 5 10 15 20 25 30 35 40 45

50 mL Single-dose NDC 0409-4902-34

50% DEXTROSE Inj., USP
25 grams (0.5 g/mL)

For I.V. use. Usual dosage: See insert.
Sterile, nonpyrogenic.
2.53 mOsmol/mL (calc.) **Rx only**
pH 4.2 (3.2 to 6.5)

Hospira

RL-0239 (5/04)

011 0 030409 490234 0

Hospira, Inc., Lake Forest, IL 60045 USA

PRINCIPAL DISPLAY PANEL - 50 mL Syringe Carton - 0409-4902-34

50 mL

NDC 0409-4902-34

50 %

DEXTROSE

Injection, USP

25 grams (0.5 g/mL)

LifeShield™

Glass

ABBOJECT®

Unit of Use Syringe

with male luer lock
adapter and
18-Gauge protected needle

Rx only

Hospira

□ **PRESS AND PULL TO OPEN**



PRINCIPAL DISPLAY PANEL - 50 mL Vial Label - 0409-6648-02

50 mL Single-dose

**50% Dextrose
Injection, USP**

**25 grams/50 mL
(0.5 g/mL)**

Hospira, Inc.
Lake Forest, IL 60045 USA

Hospira

50 mL Single-dose

**50% Dextrose
Injection, USP**

25 grams/50 mL
(0.5 g/mL)

Hospira, Inc.
Lake Forest, IL 60045 USA



NDC 0409-6648-02

Rx only

Each mL contains dextrose, hydrous 0.5 grams. May contain NaOH and/or HCl for pH adjustment. 2.53 mOsmol/mL (calc). pH 4.2 (3.2 to 6.5). Sterile, nonpyrogenic. Cleanse stopper with antiseptic. Aseptically add to a suitable solution in I.V. container or use undiluted. Use only if clear and seal is intact and undamaged. Contains no bacteriostat; use promptly; discard unused portion. For intravenous use. Usual dosage: See insert. Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]

RL-3040



(01) 0 030409 664802 4

PRINCIPAL DISPLAY PANEL - 50 mL Vial Tray - 0409-6648-02

50 mL Single-dose Fliptop Vial

25 Units/NDC 0409-6648-02

Rx only

50% Dextrose Injection, USP

25 grams/50 mL
(0.5 g/mL)

Hospira, Inc., Lake Forest, IL 60045 USA

Hospira



PRINCIPAL DISPLAY PANEL - 10 mL Syringe Label - 0409-1775-10

25% DEXTROSE (250 mg/mL)

10 mL Single-dose

Rx only

NDC 0409-1775-10

25% DEXTROSE Injection, USP

2.5 grams (250 mg/mL)

Usual Dosage: For intravenous use. See insert. Sterile, nonpyrogenic. 1.39 mOsmol/mL (calc.). pH is 4.5 (3.2 to 6.5).

Hospira

Hospira, Inc., Lake Forest, IL 60045 USA

RL-0351 (7/04)

Approx. mL **25% DEXTROSE (250 mg/mL)**

10 mL Single-dose **Rx only** NDC 0409-1775-10

25% DEXTROSE Injection, USP
2.5 grams (250 mg/mL)

Usual Dosage: For intravenous use. See insert. Sterile, nonpyrogenic. 1.39 mOsmol/mL (calc.). pH is 4.5 (3.2 to 6.5).

Hospira, Inc., Lake Forest, IL 60045 USA **Hospira** RL-0351 (7/04)

(01) 0 030409 177510 7

PRINCIPAL DISPLAY PANEL - 10 mL Syringe Carton - 0409-1775-10

10 mL

NDC 0409-1775-10

Infant

25%

DEXTROSE

Injection, USP

2.5 g

(250 mg/mL)

AnsyTM

Unit of Use Syringe

**LifeShieldTM with male
luer lock adapter**

Rx only

Hospira


Exp.

Lot

□ PRESS AND PULL TO OPEN □

Use Aseptic Technique

1. Remove luer cover.



2. Hold plunger and push barrel forward to relieve any resistance that may be present.



3. Pull the barrel down until air is expelled from the syringe.



CA-2303

Printed in USA
Hospira, Inc.
Lake Forest, IL 60045 USA

Infant
25% DEXTROSE Injection, USP
2.5 g (250 mg/mL)

Each mL contains dextrose, hydrous 250 mg. May contain HCl and NaOH for pH adjustment. 1.39 mOsmol/mL (calc.), pH is 4.5 (3.2 to 6.5). Medication and fluid path are sterile and nonpyrogenic if cap is in place and package is intact.



Infant
25% DEXTROSE Injection, USP
2.5 g

(250 mg/mL)

AnsyTM

Unit of Use Syringe

LifeShieldTM with male luer lock adapter

Rx only



Exp.
Lot

Single-dose unit. Discard unused portion. For intravenous use. Usual dosage. See insert. Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]



Infant
25% DEXTROSE Injection, USP
2.5 g (250 mg/mL)



(01) 1 030409 177510 4

10 mL NDC 0409-1775-10

10 mL NDC 0409-1775-10

Infant
25% DEXTROSE Injection, USP

Infant
25% DEXTROSE Injection, USP
2.5 g (250 mg/mL)

10 mL NDC 0409-1775-10

2.5 g (250 mg/mL)

DEXTROSE

dextrose monohydrate injection, solution

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0409-7517
Route of Administration	INTRAVENOUS		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
DEXTROSE MONOHYDRATE (UNII: LX22YL083G) (ANHYDROUS DEXTROSE - UNII:5SL0G7R0OK)	DEXTROSE MONOHYDRATE	25 g in 50 mL

Inactive Ingredients

Ingredient Name	Strength
WATER (UNII: 059QF0KO0R)	
SODIUM HYDROXIDE (UNII: 55X04QC32I)	
HYDROCHLORIC ACID (UNII: QTT17582CB)	

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0409-7517-15	10 in 1 CONTAINER	08/01/2005	08/01/2005
1		1 in 1 CARTON		
1		50 mL in 1 SYRINGE, PLASTIC; Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)		
2	NDC:0409-7517-16	10 in 1 CONTAINER	12/02/2005	
2		1 in 1 CARTON		
2		50 mL in 1 SYRINGE, PLASTIC; Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA019445	08/01/2005	

DEXTROSE

dextrose monohydrate injection, solution

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0409-4902
Route of Administration	INTRAVENOUS		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
DEXTROSE MONOHYDRATE (UNII: LX22YL083G) (ANHYDROUS DEXTROSE - UNII:5SL0G7R0OK)	DEXTROSE MONOHYDRATE	25 g in 50 mL

Inactive Ingredients

Ingredient Name	Strength
WATER (UNII: 059QF0KO0R)	
SODIUM HYDROXIDE (UNII: 55X04QC32I)	
HYDROCHLORIC ACID (UNII: QTT17582CB)	

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0409-4902-34	10 in 1 CONTAINER	12/07/2005	
1		1 in 1 CARTON		
1		50 mL in 1 SYRINGE; Type 1: Convenience Kit of Co-Package		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
UNAPPROVED DRUG OTHER		12/07/2005	

DEXTROSE

dextrose monohydrate injection, solution

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0409-6648
Route of Administration	INTRAVENOUS		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
DEXTROSE MONOHYDRATE (UNII: LX22YL083G) (ANHYDROUS DEXTROSE - UNII:5SL0G7R0OK)	DEXTROSE MONOHYDRATE	25 g in 50 mL

Inactive Ingredients

Ingredient Name	Strength
WATER (UNII: 059QF0KO0R)	
SODIUM HYDROXIDE (UNII: 55X04QC32I)	
HYDROCHLORIC ACID (UNII: QTT17582CB)	

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0409-6648-02	25 in 1 TRAY	03/31/2005	
1		50 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA019445	03/31/2005	

Labeler - Hospira, Inc. (141588017)**Establishment**

Name	Address	ID/FEI	Business Operations
Hospira, Inc.		093132819	ANALYSIS(0409-4902, 0409-6648, 0409-7517) , LABEL(0409-4902, 0409-6648, 0409-7517) , MANUFACTURE(0409-4902, 0409-6648, 0409-7517) , PACK(0409-4902, 0409-6648, 0409-7517)

Establishment

Name	Address	ID/FEI	Business Operations
Hospira, Inc.		827731089	ANALYSIS(0409-4902, 0409-6648, 0409-7517)

Revised: 3/2018

Hospira, Inc.